The thesis

Incyte Corporation is a biopharmaceutical firm with a 37.7% YoY revenue growth. Its high gross margin of 9262.0% and net margin of 2771.0% indicate strong profitability. The company's conviction score is 11/100, placing it on the WATCHLIST, despite an analyst consensus rating of BUY. The significant revenue growth and high margins make the setup interesting.

Why now

The current macro context, with elevated energy prices and bond yields, may lead to tighter monetary policy, but Incyte's strong revenue growth and profitability provide a buffer. The company's P/E ratio of 15.4x is relatively reasonable given its growth prospects.

What to watch

To confirm or deny the thesis, watch Incyte's upcoming revenue growth and margin stability over the next 1-3 quarters. Monitor the company's pipeline progress and potential new therapy approvals.

Key risks

The key risks include valuation risk given the DCF intrinsic value of $106, execution risk in maintaining high revenue growth, and competitive risk from other biotech firms. A slowdown in revenue growth or increased competition could invalidate the thesis.

Theme exposure